Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK2376497
Drug: 0.9% sodium chloride

First Posted Date: 2012-03-06

Last Posted Date: 2017-07-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 82

Registration Number: NCT01545570

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Phase 2

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Pneumococcal vaccine GSK2189242A
Biological: Placebo
Biological: Prevnar 13®
Biological: PedvaxHIB®

First Posted Date: 2012-03-06

Last Posted Date: 2019-12-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1806

Registration Number: NCT01545375

Locations: 🇺🇸
GSK Investigational Site, Shiprock, New Mexico, United States

A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: SERETIDE Diskus
Drug: SERETIDE Rotacaps

First Posted Date: 2012-02-29

Last Posted Date: 2018-06-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT01540708

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Experimental paracetamol formulation
Drug: Marketed paracetamol

First Posted Date: 2012-02-29

Last Posted Date: 2014-11-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT01540721

Locations: 🇺🇸
MDS Pharma Services NEBRASKA, Lincoln, Nebraska, United States

Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Experimental paracetamol formulation
Drug: Marketed paracetamol

First Posted Date: 2012-02-29

Last Posted Date: 2014-11-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT01540734

Locations: 🇺🇸
MDS Pharma Services NEBRASKA, Lincoln, Nebraska, United States

Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Requip PR

First Posted Date: 2012-02-22

Last Posted Date: 2018-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 295

Registration Number: NCT01536574

Locations: 🇨🇳
GSK Investigational Site, Tianjin, China

Effects of Salmeterol on Autonomic Nervous System

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Salmeterol

First Posted Date: 2012-02-22

Last Posted Date: 2014-04-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT01536587

Locations: 🇩🇪
GSK Investigational Site, Goettingen, Niedersachsen, Germany

Nicotine Lozenge Bioequivalence Study

Phase 1

Completed

Conditions: Smoking Cessation

Interventions: Drug: Nicotine (2 mg)
Drug: Nicotine (4 mg)

First Posted Date: 2012-02-22

Last Posted Date: 2013-04-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 50

Registration Number: NCT01536704

Locations: 🇺🇸
Celerion NEBRASKA, Lincoln, Nebraska, United States

Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers

Phase 4

Completed

Conditions: Hypothyroidism

Interventions: Drug: Levothyroxine

First Posted Date: 2012-02-22

Last Posted Date: 2013-02-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT01536678

Locations: 🇮🇳
GSK Investigational Site, Hyderabad, India

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Phase 3

Terminated

Conditions: Crohn's Disease

Interventions: Drug: GSK1605786A

First Posted Date: 2012-02-22

Last Posted Date: 2018-01-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 255

Registration Number: NCT01536418

Locations: 🇬🇧
GSK Investigational Site, Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy